BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 25825260)

  • 1. Decitabine as a conditioning regimen in haploidentical stem cell transplantation for refractory acute myeloid leukaemia.
    Zhang C; Chen XH; Liu J; Gao L; Liu Y; Gao L; Kong PY; Zhang X
    J Clin Pharm Ther; 2015 Jun; 40(3):336-8. PubMed ID: 25825260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decitabine prior to salvaged unrelated cord blood transplantation for refractory or relapsed childhood acute leukemia.
    Zhou H; Zheng C; Zhu X; Tang B; Tong J; Zhang X; Zhang L; Liu H; Sun Z
    Pediatr Transplant; 2016 Dec; 20(8):1117-1124. PubMed ID: 27620713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case report.
    Jin M; Hu Y; Wu W; Luo Y; Tan Y; Yu J; Jin A; Yang L; Huang H; Wei G
    BMC Cancer; 2019 Mar; 19(1):242. PubMed ID: 30885156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Decitabine Combined with Unrelated Cord Blood Transplantation in an Adult Patient with -7/EVI1+ Acute Myeloid Leukemia: a Case Report and Literature Review.
    Jiang YZ; Su GP; Dai Y; He HS; Huang LQ; Sun ZM; Huang DP
    Ann Clin Lab Sci; 2015; 45(5):598-601. PubMed ID: 26586716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of priming with recombinant human granulocyte colony-stimulating factor on conditioning regimen for high-risk acute myeloid leukemia patients undergoing human leukocyte antigen-haploidentical hematopoietic stem cell transplantation: a multicenter randomized controlled study in southwest China.
    Gao L; Wen Q; Chen X; Liu Y; Zhang C; Gao L; Kong P; Zhang Y; Li Y; Liu J; Wang Q; Su Y; Wang C; Wang S; Zeng Y; Sun A; Du X; Zeng D; Liu H; Peng X; Zhang X
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):1932-9. PubMed ID: 25109850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Outcome of haploidentical hematopoietic stem cell transplantation for refractory/relapsed acute leukemia].
    Wang Y; Liu DH; Liu KY; Xu LP; Zhang XH; Han W; Chen H; Chen YH; Wang FR; Wang JZ; Fu HX; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):917-21. PubMed ID: 23363748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies of decitabine with allogeneic progenitor cell transplantation.
    Giralt S; Davis M; O'Brien S; van Besien K; Champlin R; de Vos D; Kantarjian H
    Leukemia; 1997 Mar; 11 Suppl 1():S32-4. PubMed ID: 9130690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
    Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Salvaged allogeneic hematopoietic stem cell transplantation for refractory/recurrent acute myeloid leukemia].
    Wang JB; Wu T; DA WM; Tong CR; Sun Y; Zhao YL; Yin YM; Cao XY; Lu Y; Gao YQ; Zhou JR; Zhang JP; Luo RM; Zou W; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jun; 33(6):467-70. PubMed ID: 22967382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study.
    Guièze R; Cornillet-Lefebvre P; Lioure B; Blanchet O; Pigneux A; Recher C; Bonmati C; Fegueux N; Bulabois CE; Bouscary D; Vey N; Delain M; Turlure P; Himberlin C; Harousseau JL; Dreyfus F; Béné MC; Ifrah N; Chevallier P;
    Am J Hematol; 2012 Dec; 87(12):1052-6. PubMed ID: 22911473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia.
    Steckel NK; Groth C; Mikesch JH; Trenschel R; Ottinger H; Kordelas L; Mueller-Tidow C; Schliemann C; Reicherts C; Albring JC; Silling G; Schmidt E; Berdel WE; Lenz G; Ditschkowski M; Beelen DW; Stelljes M
    Br J Haematol; 2018 Mar; 180(6):840-853. PubMed ID: 29468631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT).
    Ganguly S; Amin M; Divine C; Aljitawi OS; Abhyankar S; McGuirk JP
    Ann Hematol; 2013 Apr; 92(4):549-50. PubMed ID: 23111661
    [No Abstract]   [Full Text] [Related]  

  • 13. Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
    You Y; Li QB; Chen ZC; Li WM; Xia LH; Zhou H; Zou P
    Chin Med J (Engl); 2008 Sep; 121(18):1770-4. PubMed ID: 19080355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.
    Khan N; Hantel A; Knoebel RW; Artz A; Larson RA; Godley LA; Thirman MJ; Liu H; Churpek JE; King D; Odenike O; Stock W
    Leuk Lymphoma; 2017 Sep; 58(9):1-7. PubMed ID: 28278716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study.
    Stahl M; DeVeaux M; Montesinos P; Itzykson R; Ritchie EK; Sekeres MA; Majhail N; Barnard J; Podoltsev NA; Brunner AM; Komrokji RS; Bhatt VR; Al-Kali A; Cluzeau T; Santini V; Roboz GJ; Fenaux P; Litzow M; Fathi AT; Perreault S; Kim TK; Prebet T; Vey N; Verma V; Kobbe G; Bergua J; Serrano J; Gore SD; Zeidan AM
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1754-1758. PubMed ID: 29649620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
    Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
    Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
    Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia.
    Chemnitz JM; von Lilienfeld-Toal M; Holtick U; Theurich S; Shimabukuro-Vornhagen A; Krause A; Brossart P; Hallek M; Scheid C
    Ann Hematol; 2012 Jan; 91(1):47-55. PubMed ID: 21584670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT).
    Aoudjhane M; Labopin M; Gorin NC; Shimoni A; Ruutu T; Kolb HJ; Frassoni F; Boiron JM; Yin JL; Finke J; Shouten H; Blaise D; Falda M; Fauser AA; Esteve J; Polge E; Slavin S; Niederwieser D; Nagler A; Rocha V;
    Leukemia; 2005 Dec; 19(12):2304-12. PubMed ID: 16193083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative analysis of decitabine combined with DAG regimen and other regimens in treatment of refractory/relapsed acute myeloid leukemia].
    Hao J; Wang L; Wang Y; Liu Z; Gu X; Liu J; Li L; Duan Y; Chen Y; Zhao W; Shen Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jun; 35(6):481-5. PubMed ID: 24985167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.